Gujarat Themis Biosyn Ltd vs Themis Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 378.6 as of 06 May 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Themis Medicare Ltd changed from 7.2 on March 2021 to 45.3 on March 2025 . This represents a CAGR of 44.46% over 5 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Themis Medicare Ltd changed from ₹ 257.55 crore on March 2021 to ₹ 1349 crore on March 2025 . This represents a CAGR of 39.28% over 5 years The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Themis Medicare Ltd for the Dec '25 is ₹ 96.93 crore as compare to the Sep '25 revenue of ₹ 82.97 crore. This represent the growth of 16.83% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Themis Medicare Ltd for the Dec '25 is ₹ 15.73 crore as compare to the Sep '25 ebitda of ₹ 1.89 crore. This represent the growth of 732.28% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Themis Medicare Ltd changed from ₹ 24.68 crore to ₹ 10.09 crore over 7 quarters. This represents a CAGR of -40.02% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Themis Medicare Ltd changed from 14.84 % on March 2021 to 19.23 % on March 2025 . This represents a CAGR of 5.32% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Themis Medicare Ltd

Themis Medicare Limited was formerly incorporated as 'Themis Chemicals Limited' in 1969.
The Company was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April, 1993.
Thereafter, the name of the Company was changed to Themis Medicare Limited in 2001.
The Company is principally engaged in the business of manufacturing of finished formulations and synthetic Active Pharmaceutical Ingredients. In Mar.'95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Themis Medicare Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Themis Medicare Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,125 Cr while Market cap of Themis Medicare Ltd is 916 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Themis Medicare Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Themis Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Themis Medicare Ltd?

As of May 6, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹378.6. On the other hand, Themis Medicare Ltd stock price is INR ₹99.5.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Themis Medicare Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Themis Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.